CAMP inhibits PI3K, activates AKT, and increases GSK3 activity
New developments, such as dual and triple agonists that target the glucagon, GLP-1, and GIP receptors, promise better results
Case Example: ePA Workflow for a GLP-1 Prescription To illustrate, consider a hypothetical case: Patient: 55-year-old female with Type 2 diabetes (HbA1c 8.7%), BMI 34, on metformin + lifestyle modifications
MDD, major depressive disorder
For those who have also taken breaks from tirzepatide, restarting Mounjaro after a short break follows similar principles